Scarica l'app Stockscreener
2.69
5.61%
-0.16
Dopo l'orario di chiusura:
2.69
Metagenomi Inc Borsa (MGX) Ultime notizie
Neutral On Metagenomi's Promising Yet Highly Speculative Gene Editing Potential - Seeking Alpha
Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer - GlobeNewswire Inc.
The Market Doesn't Like What It Sees From Metagenomi, Inc.'s (NASDAQ:MGX) Revenues Yet As Shares Tumble 26% - Simply Wall St
Brokerages Set Metagenomi, Inc. (NASDAQ:MGX) Price Target at $16.67 - MarketBeat
Stargate Project’s healthcare winners: AI-led biotechs and Metagenomi - MSN
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
People are buying the wrong stock thinking it's part of OpenAI's Stargate Project - Quartz
Metagenomi aiming for clinical trials of gene-editing therapy in 2026 - Hemophilia News Today
Metagenomi outlines anticipated 2025 milestones - MSN
Metagenomi advances gene editing therapies into 2025 - Investing.com
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones - GlobeNewswire
Metagenomi Announces New Appointment to its Board of Directors - GlobeNewswire
Metagenomi, Inc. Announces Appointment of Eric Bjerkholt to Its Board of Directors, Serving on Audit and Compensation Committees, Effective January 27, 2025 - Marketscreener.com
Metagenomi, Inc.'s (NASDAQ:MGX) market cap dropped US$12m last week; individual investors who hold 33% were hit as were institutions - Yahoo Finance
We Think Metagenomi (NASDAQ:MGX) Needs To Drive Business Growth Carefully - Simply Wall St
Class Action Lawsuit Against Metagenomi Inc. (NASDAQ:MGX) - MSN
Geode Capital Management LLC Has $734,000 Position in Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Metagenomi CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Metagenomi, Inc. (NASDAQ:MGX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Metagenomi: Q3 Earnings Snapshot - Marketscreener.com
Metagenomi, Inc. (NASDAQ:MGX) Short Interest Up 445.1% in December - MarketBeat
Metagenomi, Inc. (NASDAQ:MGX) Shares Purchased by BNP Paribas Financial Markets - Defense World
Verition Fund Management LLC Makes New Investment in Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Levi & Korsinsky Reminds Metagenomi Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 25, 2024MGX - The Eastern Progress Online
MGX INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $00,000 In MGX To Contact Him Directly To Discuss Their Options - The Eastern Progress Online
2 ‘Monster’ Stocks to Snap Up Before 2025 - MSN
Metagenomi (NASDAQ:MGX) Price Target Raised to $14.00 - Defense World
MGX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Eastern Progress Online
Structure Therapeutics Inc (GPCR-Q) QuotePress Release - The Globe and Mail
2 ‘Monster’ Stocks To Snap Up Before 2025 - Barchart
Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your RightsMGX - The Eastern Progress Online
Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference 'RNA at the Bench and Bedside IV” - The Manila Times
Metagenomi Presents Highly Specific and Efficient Genome - GlobeNewswire
Metagenomi, Inc. Presents Highly Specific and Efficient Genome Editing Tools At Nature Conference RNA At the Bench and Bedside IV - Marketscreener.com
Metagenomi, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your RightsMGX - The Eastern Progress Online
MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Expert Outlook: Metagenomi Through The Eyes Of 4 Analysts - Benzinga
Metagenomi (NASDAQ:MGX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Metagenomi presents updated preclinical NHP data at ASH meeting - TipRanks
Metagenomi, Inc. (NASDAQ:MGX) Stock Catapults 106% Though Its Price And Business Still Lag The Industry - Simply Wall St
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):